Some of the most expensive medicines, biologic drugs, are major global targets for cost savings by public health agencies globally. Biosimilars, or follow-on biologics, are produced by different manufacturers when biologic drugs go off patent. With the advent of a pathway for the approval of biosimilars in the US, the US government estimates they will save up to $9 billion over a 10-year period. Biologics are distinguished from small-molecule generic drugs because of their size and complexity which preclude the standard determination of bioequivalence that is used in the approval of generics. 

Of the Western countries, Australia (in 2004) was the first to approve a biosimilar product. Since then, the developments facilitating biosimilars have gained momentum, with significant commercial opportunities emerging. The relatively new concept of biosimilars and the technical complexity of creating the comparable products have created a need for educational forums to share the limited experiences acquired to date.

The BioSimilar Symposium in October has now been incorporated into the Wednesday Program of TRX10. Click here to view the prefinal program.

Proudly Sponsored by: